7:15 am Registration & Coffee Room Networking
Accelerating the Future of the Allogeneic Field with Novel Innovation, Strategy & Clinical Data
8:15 am Opening Remarks
8:30 am Industry Leaders Fireside Chat: Highlights & Hurdles from the Past Year to Inform Your 2024 Strategy
Synopsis
- A panel discussion with the C-level leaders who are innovating in the allogeneic cell therapy field
- Highlighting and celebrating the big wins for allogeneic therapies in the last year
- Considering the challenges and the strategy required to overcome them
9:00 am Full Landscape Overview of the Allogeneic Cell Therapy Space
Synopsis
- Assessing how allogeneic cell therapies align with the rest of the cell therapy landscape
- What does the existing allogeneic landscape consist of and how has it changed over recent years?
- Insights into potential trends and the potential future of allogeneic therapies for oncology
9:30 am Caribou Biosciences: Pre-Clinical & Clinical Data Presentation
Synopsis
- Comprehensive presentation of recent advancements in allogeneic research through pre-clinical data
- Exploration of the clinical data landscape, showcasing the in-patient impact of Caribou Biosciences’ innovative approaches
- Discussion on potential implications and next steps derived from the amalgamation of pre-clinical and clinical data in Caribou Biosciences’ presentation
10:00 am Morning Refreshment Break & Speed Networking
Synopsis
As the allogeneic community is reunited, this session will ensure you can reconnect with your peers in the room to make new and lasting connections. Also, don’t forget to enjoy some refreshments before we split off into the 3 different tracks: Pre-Clinical, Clinical and Manufacturing & Process Development
PRE-CLINICAL TRACK
Improving Pre-Clinical Models to Better Prepare Allogeneic Therapies for the Clinic
11:30 am Innovative Model Strategies for Enhanced Translatability & Predictivity vs. Traditional Approaches in Pre-Clinical Research
Synopsis
- Investigating novel approaches for allogeneic therapies, like canine models, to enhance translatability to human patients
- Harnessing the power of organ-on-a-chip modeling to gain unprecedented insights and overcome constraints associated with traditional rodent models
- Navigating the dynamic landscape of alternatives to animal models, embracing AI and computational methodologies for improved pre-clinical modeling of allogeneic cell therapies
12:00 pm Exploring the Applications of B-Cells in Novel Off-theShelf Therapies
Synopsis
- Utilizing CRISPR/Cas gene editing technologies to prepare B-cells for therapeutic applications
- B-cells can be differentiated into long-lived plasma cells, which have naturally allogeneic properties
- Pre-clinical model development to evaluate B-Cell medicine alloresistence
CLINICAL TRACK
Implementing Effective Allogeneic Donor Selection & Management
11:30 am Insights from INB-100 Trial Expansion Cohort: Unveiling Progress & Challenges
Synopsis
- Exploring the advantages of haplo-matching patients for streamlined donor selection and reduced immunogenicity
- Unveiling the expansion and persistence of gamma delta cells and the implications for improving durability for other cell types
- How can data from leukemia trials be effectively translated into strategies for advancing clinical trials targeting solid tumors?
12:00 pm Dose Escalation for Allogeneic CAR-T Cell Therapies, Clinical & Translational Updates
Synopsis
- Clinical efficacy with fully in-house manufactured CAR-T cells
- The importance of biomarkers in optimizing treatment dosing and balancing efficacy with safety in clinical data
MANUFACTURING & PROCESS DEVELOPMENT TRACK
Upscaling Manufacturing for Allogeneic Cell Therapies to Meet Rising Demands
11:30 am What are the Opportunities for Using Automation in Upscaling Allogeneic Manufacturing?
Synopsis
- Uncovering opportunities to implement automation for increased efficiency and consistency in allogeneic manufacturing processes
- What recent technological advancements can we take advantage of in the automation of manufacturing off-the-shelf cell therapies?
- Examining how automated systems can streamline production, reduce errors, and enhance scalability in manufacturing operations
12:00 pm Using Agile Process Development to De-Risk the Upscaling of Your Manufacturing Process
Synopsis
- Understanding the benefits of preparing your products for upscaled manufacturing
- Maximizing data collection from early well data to ease progress to bioreactors
- Presenting data from a scaled-down bioreactor to ease the transition from lab to manufacturing
12:30 pm Lunch Refreshment
2:00 pm Leveraging In Vitro Models to Streamline Transition to the Clinic
Synopsis
- Utilizing 3D in vitro models to more accurately model safety and efficacy of allogeneic therapies
- Gaining insights into regulatory expectations, compliance, and data requirements for successful model validation
- Leveraging clinical data collected during pre-clinical research for streamlined transition to the clinic
Revolutionary Novel Modifications to Enhance the Potency of Off-the-Shelf Therapies
2:30 pm Evolving Cell Constructs Beyond CAR to Make Truly Off-the-Shelf Cell Therapies
Synopsis
- Elevating cell engineering strategies beyond CAR to reduce risk of toxicity in patients
- Taking a unique fit-for-purpose approach to tailor allogeneic therapies and reduce costs
- Considering safety concerns presented by excessive modifications of cell constructs
3:00 pm Innovative Strategies for Improving Potency of Allogeneic Gamma Delta Cell Therapies
Synopsis
- Introducing a novel manufacturing process tailored for T2 blood-derived gamma delta cells to amplify potency
- Implementing an adaptable CAR structure specifically designed for gamma deltas to optimize their therapeutic capabilities
- Utilizing an inducible variant of IL18, establishing a functional link to T-cell activation for enhanced therapeutic effects
3:30 pm Durable Multiplex Epigenetic Editing to Enhance Allogeneic CAR-T Therapies
Synopsis
- Demonstrating the robustness of multiplex epigenetic editing in primary T-cells to suppress target gene expression without introduction of genomic rearrangements
- Eliminating in vitro GvHD response and enhancing resistance to CD8+ and CD4+ T-cell alloreactivity with a multiplex epigenetic editing strategy
- Producing multiplex epigenetically-edited CAR-T cells with robust anti-tumor function
2:00 pm Clinical Safety & Immunogenicity Monitoring Strategies for Edited CAR-T Cell Therapy
Synopsis
- Monitoring of on- and off-target editing events and clonotype characterization in patients
- Monitoring for immunogenicity and tumorigenicity in patients
Spotlighting Recent Allogeneic Clinical Successes
2:30 pm Reporting Clinical Data from a First-in-Class Plasmacytoid Dendritic Cell Line Vaccine in Patients with Metastatic NSCLC
Synopsis
- Exploring the features and potential applications of the innovative PDC*vac technology as a novel cancer vaccine
- Unveiling new clinical safety and efficacy data from the most recent cohort of patients with NSCLC to support prior findings
- Using recent findings to direct future research and accelerate the treatment of patients with advanced solid tumors
3:00 pm Expanding a Clinically Informed Pipeline in Autoimmune Diseases & Oncology
Synopsis
- Clinical progress for a 1st in class CAR gamma delta T-cell in oncology
- Leveraging key clinical-translational learnings to inform development and pipeline expansion in autoimmune conditions
- Clinical advancement of next generation armored CAR-T cells in solid tumors
3:30 pm Panel Discussion: Is the Future for Allogeneic Therapies as Mono-Therapy or Combination?
Synopsis
- Engaging in a panel discussion to explore the future landscape of allogeneic therapies as monotherapies or in combination
- Evaluating the advantages and challenges of each approach from clinical and commercial perspectives
2:00 pm Preparing Your Supply Chain for Growing Demand for Allogeneic Products
Synopsis
- Assessing the challenges and opportunities in preparing the supply chain to meet the growing demand for allogeneic products
- Discussing strategies for optimizing supply chain logistics, minimizing bottlenecks, and ensuring timely delivery
- What steps can be proactively taken today to prepare your supply chain of the future?
Sourcing & Selecting Optimal Starting Material for Allogeneic Engineering
2:30 pm Unveiling the Role of iPSCs in the Advancement of Allogeneic Cell Therapies
Synopsis
- Discussing how iPSCs can contribute to the scalability, reproducibility, and customization of allogeneic therapies
- Showcasing recent breakthroughs achieved through leveraging iPSC technology in the field of allogeneic cell therapies
- How can iPSC technologies be utilized to overcome current clinical and manufacturing challenges for allogeneic therapies?
3:00 pm Characterizing Starting Material for Safety & Efficacy
Synopsis
- Discussing the critical importance of comprehensive characterization of starting materials for ensuring safety and efficacy in allogeneic cell therapies
- Exploring methodologies and technologies for thorough characterization, addressing regulatory requirements
- Highlighting the potential of induced pluripotent stem cells (iPSCs) and their benefits as allogeneic starting materials
3:30 pm Panel Discussion: What Criteria Make the Ideal Starting Material for Allogeneic Products?
Synopsis
- A discussion around identifying and improving starting materials for allogeneic products
- What weaknesses remain in current starting materials that the industry must overcome?
- What is the true benefit of a ‘perfect’ starting material when considering the final product?
4:00 pm Afternoon Break & Tech Slam
5:00 pm Sanofi: Clinical Data Presentation
Synopsis
- Presenting refreshed data from ongoing clinical and pre-clinical research
- Advancing the immunotherapy field to bring effective treatments to patients
- Looking to the future of allogeneic cell therapies from a pharmaceutic perspective
5:30 pm Overcoming Hurdles in Allogeneic Cell Therapy Development Using Pooled Donor Cord Blood CD34+ Cells as the Starting Material
Synopsis
- Highlighting the benefits and opportunities of utilizing cord blood as a starting material
- Considering the potential benefits and risks of pooled donor manufacturing
- Discussion of Deverra’s platform and clinical outcomes using pooled donor allogeneic cell therapy in upfront AML
6:00 pm Closing Remarks & End of Day One
6:15 pm Drinks Reception
Synopsis
Reunite with old friends and meet new industry peers after a busy day of innovation.